Uveal melanoma

This phase 3 trial tested a personalized vaccine made from a patient's own immune cells and tumor RNA in 200 people with a high-risk form of eye cancer (uveal melanoma with monosomy 3). After surgery to remove the tumor, half received the vaccine over two years and half were simp…

This trial tests a treatment called Melphalan/HDS for people whose eye melanoma has spread to the liver. The approach delivers high-dose melphalan, a chemotherapy drug, straight into the liver through a device system while limiting exposure to the rest of the body. Researchers wa…

This early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…

This phase II trial tests whether combining pembrolizumab (an immunotherapy) with lenvatinib (a targeted therapy) can control metastatic uveal melanoma, a rare eye cancer that has spread. About 51 adults are enrolled in two groups: those who have never taken Tebentafusp and those…

This trial investigates whether combining two immunotherapy drugs (ipilimumab and nivolumab) with a procedure called immunoembolization can help people whose uveal melanoma has spread to the liver. The drugs help the immune system attack cancer cells, while immunoembolization cut…

This phase 3 trial tested whether a yeast-derived immune stimulant (GM-CSF) and a peptide vaccine, alone or together, could prevent melanoma from returning after surgery. 815 patients with no visible cancer after complete surgical removal of advanced melanoma were randomly assign…

This study tested a combination of two drugs, sitravatinib (a pill) and tislelizumab (an IV infusion), in 16 people with a rare eye cancer (uveal melanoma) that had spread to the liver. The goal was to see if the combo could shrink liver tumors better than current treatments. Par…

This phase 2 trial tested the drug darovasertib in 15 people with high-risk uveal melanoma (a rare eye cancer) who were scheduled for eye removal surgery. Participants took the drug for up to 4 weeks before surgery, and some continued for 6 months afterward. The main goals were t…

This early-phase trial tested a new personalized therapy called TBio-4101 for people with advanced melanoma that had stopped responding to standard treatments. The therapy uses a patient's own tumor-fighting immune cells, which are collected, multiplied in the lab, and then infus…

This study tested a new drug called IMCgp100 in 378 adults with a specific genetic type (HLA-A*0201) of advanced uveal melanoma, a rare eye cancer. Participants received either IMCgp100 or one of three standard treatments (dacarbazine, ipilimumab, or pembrolizumab). The main goal…

This early-stage trial tested a personalized vaccine made from a patient's own immune cells and tumor material for people with metastatic uveal melanoma, a rare eye cancer that has spread. The vaccine was added to standard treatments like immunotherapy or chemotherapy. The main g…

This study tested the drug sorafenib (Nexavar) in 32 adults with uveal melanoma that had spread to other parts of the body. The goal was to see if the drug could stop tumors from growing for at least 24 weeks. Sorafenib is already used for other cancers, and researchers wanted to…

This study tested whether a combination of two drugs, nivolumab and relatlimab, can shrink tumors in people with metastatic uveal melanoma, a rare eye cancer that has spread. Twenty-seven participants received the treatment to see how many responded. The goal was to control the d…

This early-phase study tested a new drug called IN10018, alone or with other medicines, in 51 adults with advanced melanoma that had spread. The main goal was to check safety and how the body handles the drug. The study included people with two hard-to-treat types of melanoma: uv…

This study tested a treatment for uveal melanoma that has spread to the liver. Tiny radioactive beads were injected into the liver's blood vessels to deliver radiation directly to tumors. The goal was to shrink or control the liver tumors. 48 patients took part, and the study loo…

This phase 2 trial tested a drug called Taxoprexin (DHA-paclitaxel) in 22 people with metastatic uveal melanoma, a rare eye cancer that has spread. The drug was given weekly for 5 weeks in a 6-week cycle. The main goal was to see if tumors shrank or disappeared, and to check safe…

This early-phase trial tested whether it is safe and feasible to give patients their own immune cells (called tumor infiltrating lymphocytes, or TIL) directly into the liver artery. Eight adults with melanoma that had spread to the liver received the TIL infusion along with chemo…

This early-phase study tested a single dexamethasone implant (Ozurdex) in 10 people with uveal melanoma who had fluid buildup under the retina after radiation treatment. The goal was to see if the implant is safe and can help reduce the fluid to prevent vision loss. The implant i…

This study looked at whether starting supportive care early, alongside standard cancer treatment, helps patients with metastatic uveal melanoma feel more supported. 162 adults with advanced eye cancer that had spread were randomly assigned to get either standard oncology visits o…

This study looked at the DNA changes (mutations) in eye cancers called ocular melanoma. Researchers analyzed tumor samples from 58 patients to understand how these cancers develop and spread. The goal was to identify key mutations that could lead to better treatments in the futur…

This study aimed to create a communication tool to help doctors and patients discuss when cancer stops responding to treatment. Researchers interviewed 128 people, including patients with certain breast cancers, metastatic uveal melanoma, parents of children with cancer, and heal…

This study looked at whether measuring tumor DNA in the blood can help doctors know if surgery to remove liver metastases from uveal melanoma was successful. Researchers took blood samples from 60 patients before and after surgery and during follow-up. The goal was to see if chan…